Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesVectus Biosystems Ltd

Vectus Biosystems Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.05 AUD -0.01 ( 16.67%)
Last update at 2026-11-12T04:46:00Z
VOLUME
309789
Market Cap
4.66M
P/E
2.50

Momentum Score

…

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.05
Low
0.06
High
52 Week Price Range
0.07
Low
0.46
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Vectus Biosystems Ltd (ASX: VBS) is limited; company filings and disclosures provide few operational details. Potential long-term growth drivers may include successful product development, regulatory approvals and commercial adoption of any therapeutics or technologies it pursues, which could support revenue expansion and scale. Investors may find the company attractive if milestone-driven de-risking occurs.

Key risks include limited disclosure, clinical and regulatory uncertainty, small-cap liquidity and funding requirements that could cause dilution, and execution risk commercialising products.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.06
Dividend Yield
-
Revenue TTM
2.77M
Revenue Per Share
0.05
Gross Profit TTM
2.77M
Debt / Equity
0.24
ROE
139.32%
Net Debt
-0.17M
ROCE
-48.64%
Diluted EPS TTM
0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 1.35M -1.78M -3.40M -3.45M -3.99M
Net income 1.56M -1.78M -2.34M -3.45M -4.69M
Selling general administrative - 0.95M 0.78M 2.57M 2.04M
Selling and marketing expenses - 0.55M 1.48M - -
Gross profit -0.00M 0.48M 1.14M - -
Reconciled depreciation - - 0.06M 0.05M 0.02M
Ebit -1.37M -1.70M -2.33M -3.24M -3.30M
Ebitda -1.36M -1.69M -2.27M -3.20M -3.28M
Depreciation and amortization 0.00M 0.01M 0.06M 0.05M 0.02M
Operating income -1.37M -1.69M -2.27M -3.24M -3.30M
Other operating expenses 1.37M 2.17M 3.41M 4.60M 4.60M
Interest expense 0.04M 0.00M 0.01M 0.21M 0.69M
Tax provision - - 0.00M 0.00M 0.00M
Interest income - 0.00M 0.08M 0.06M 0.00M
Net interest income - - 0.07M -0.15M -0.69M
Income tax expense -0.21M -0.46M -1.06M 1.50M 0.69M
Total revenue - 0.48M 1.14M 0.06M 1.30M
Total operating expenses 1.36M 2.17M 3.41M 4.60M 4.60M
Cost of revenue 0.00M - 0.06M - -
Total other income expense net 2.72M -0.09M -1.13M 1.30M -0.69M
Net income from continuing ops - - -2.34M -3.45M -3.99M
Net income applicable to common shares - -1.78M -2.34M -3.45M -3.99M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 3.82M 0.78M 2.03M 4.63M 3.94M
Other current assets 0.06M 0.09M 0.06M 1.43M 2.32M
Total liab 1.50M 1.04M 0.57M 1.11M 7.47M
Total stockholder equity 2.32M -0.26M 1.45M 3.52M -3.53M
Other current liab 0.35M 0.30M 0.37M 0.36M 0.89M
Common stock 39.17M 38.37M 38.37M 38.35M 27.30M
Capital stock - - - 38.35M 28.19M
Retained earnings -37.77M -39.50M -37.76M -35.63M -32.18M
Other liab - - - 0.00M 0.07M
Cash 0.72M 0.25M 0.81M 2.95M 1.28M
Total current liabilities 1.00M 0.84M 0.57M 1.08M 7.40M
Current deferred revenue - - - 0.45M 0.44M
Net debt -0.17M -0.05M -0.78M -2.88M 4.73M
Short term debt 0.05M - 0.03M 0.04M 5.95M
Short long term debt - - - - 5.89M
Short long term debt total 0.55M 0.20M 0.03M 0.07M 6.02M
Other stockholder equity - - - -2.72M 0.89M
Property plant equipment - - - 0.17M 0.21M
Total current assets 3.80M 0.78M 1.84M 4.46M 3.73M
Net tangible assets - - - 3.52M -3.53M
Short term investments 2.80M - - - -
Net receivables 0.22M 0.44M 0.98M 0.07M 0.13M
Long term debt - - - - 0.00M
Inventory - 0.00M 0.00M 0.00M 0.00M
Accounts payable 0.60M 0.53M 0.17M 0.22M 0.12M
Accumulated other comprehensive income 0.92M 0.88M 0.84M 0.80M 0.46M
Non currrent assets other - - - -0.17M -0.21M
Non current assets total 0.02M 0.00M 0.18M 0.17M 0.21M
Capital lease obligations - - - 0.07M 0.13M
Long term debt total - - - 0.03M 0.07M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -0.07M -0.02M -
Change to liabilities - - - 0.10M -0.20M
Total cashflows from investing activities - 0.10M -0.07M -0.02M -0.02M
Net borrowings - - - -0.50M -0.03M
Total cash from financing activities 1.04M 0.17M -0.04M 4.04M -0.03M
Change to operating activities - - - 0.71M -0.77M
Net income 1.56M -1.78M -2.34M -3.45M -3.99M
Change in cash 0.47M -0.56M -2.14M 1.67M -4.50M
Begin period cash flow 0.25M 0.81M 2.95M 1.28M 5.78M
End period cash flow 0.72M 0.25M 0.81M 2.95M 1.28M
Total cash from operating activities -0.57M -0.83M -2.03M -2.35M -4.44M
Issuance of capital stock - - - 4.60M -
Depreciation 0.00M 0.01M 0.06M 0.05M 0.02M
Other cashflows from investing activities - 0.10M - - 0.00M
Dividends paid - - - - 4.10M
Sale purchase of stock - - 0.00M -0.06M -0.06M
Other cashflows from financing activities - - -0.04M -0.06M -0.03M
Change to netincome - - - 0.23M 0.48M
Capital expenditures 0.00M 0.00M 0.07M 0.02M 0.02M
Change in working capital 0.58M 0.64M 0.24M 2.20M 0.00M
Stock based compensation - 0.03M 0.06M 0.00M 0.01M
Other non cash items -2.72M 0.26M -0.05M 1.05M -0.48M
Free cash flow -0.57M -0.83M -2.10M -2.37M -4.46M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VBS
Vectus Biosystems Ltd		 -0.01
16.67%		 0.05 2.50 - 1.69 2.01 156321.21 1.05
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Vectus Biosystems Ltd

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.

26-34 Dunning Avenue, Rosebery, NSW, Australia, 2018

61 2 8344 1300

https://www.vectusbiosystems.com.au

Name Title Year Born
Dr. Karen Annette Duggan CEO & Exec. Director NA
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin Company Sec. NA
Prof. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC Consultant NA
Dr. Karen Annette Duggan CEO & Executive Director NA
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin Company Secretary NA
Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D. Consultant NA
Dr. Karen Annette Duggan CEO & Executive Director NA
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFin Company Secretary NA
Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D. Consultant NA
Dr. Karen Annette Duggan CEO & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…